- MYC protein plays a dual role in cancer cells, driving growth and repairing DNA damage.
- High levels of MYC in tumors make them resistant to chemotherapy and radiation.
- MYC protein recruits DNA repair machinery to broken DNA strands caused by treatment.
- This unexpected function of MYC could explain why some cancers relapse after initial treatment.
- MYC’s dual role may make it a difficult target for cancer therapies, but also a potential survival lifeline for malignant cells.
Why do some cancers resist chemotherapy even when treatments successfully damage their DNA? This question has long puzzled oncologists, especially in aggressive tumors where initial responses are often followed by rapid relapse. Now, scientists have uncovered a surprising answer: a single protein, long known for driving cancer growth, may also be helping tumors heal themselves after treatment. The culprit is MYC, one of the most frequently overactive proteins in cancer, now shown to play a second, unexpected role — not just accelerating cell division, but also rushing to repair broken DNA strands caused by chemotherapy and radiation. This dual function could explain why cancers with high MYC levels are so difficult to eradicate, turning a well-known accelerator of tumor growth into a survival lifeline for malignant cells.
\n\n
What Does MYC Actually Do in Cancer Cells?
\n
MYC is a transcription factor that regulates the expression of thousands of genes involved in cell growth, metabolism, and proliferation. In many cancers — including aggressive forms of breast, lung, and blood cancers — MYC is either overproduced or hyperactivated, pushing cells into a state of uncontrolled division. But recent research reveals it does more than just fuel growth. When DNA is damaged by chemotherapy or radiation, MYC rapidly relocates to the sites of DNA breaks, where it directly recruits key components of the DNA repair machinery, such as the MRN complex (MRE11-RAD50-NBS1) and BRCA1. This ability transforms MYC from a mere growth promoter into an active participant in genome maintenance. By coordinating the repair of treatment-induced damage, MYC gives cancer cells a second chance to survive, undermining the very therapies designed to kill them. This discovery, published in Nature, redefines our understanding of how oncogenes contribute to treatment resistance.
\n\n
What Evidence Supports MYC’s Role in DNA Repair?
\n
In a series of experiments using human cancer cell lines and mouse models, researchers observed that MYC physically binds to double-strand DNA breaks within minutes of damage induction. Using chromatin immunoprecipitation and live-cell imaging, they tracked MYC accumulating at break sites, where it interacts with repair proteins to stabilize the repair complex. When MYC was genetically silenced, cancer cells showed significantly reduced DNA repair capacity and became markedly more sensitive to chemotherapy and radiation. In one study, MYC-deficient tumors shrank by over 60% more than MYC-active ones after treatment. These findings were further validated in patient tumor samples: high MYC expression correlated with increased markers of DNA repair activity and poorer response to therapy. As Dr. Laura Soucek, a cancer biologist at the Vall d’Hebron Institute in Barcelona who was not involved in the study, told Reuters, “MYC is not just a gas pedal — it’s also a mechanic fixing the damage the car sustains while speeding.”
\n\n
Are There Reasons to Question This New Role?
\n
While the evidence for MYC’s involvement in DNA repair is compelling, some scientists caution against oversimplifying its role. MYC is a master regulator with vast influence over cellular processes, and its presence at DNA breaks might be a byproduct of its general chromatin-binding activity rather than a direct repair function. Others argue that MYC’s primary contribution to resistance may stem from its ability to promote cell cycle progression and metabolic adaptation, which indirectly support survival under stress. Additionally, not all cancer types show the same dependency on MYC for repair; in tumors with intact p53 pathways, alternative repair mechanisms may compensate. There is also concern that targeting MYC could harm normal cells, given its essential roles in tissue regeneration and immune function. As such, while the therapeutic implications are exciting, researchers stress the need to understand the context in which MYC-driven repair dominates — and whether blocking it would be safe and effective in patients.
\n\n
What Are the Real-World Consequences of This Discovery?
\n
This discovery could reshape how we treat MYC-driven cancers, which account for up to 70% of human malignancies. Current therapies often fail because they don’t account for MYC’s dual role — attacking rapidly dividing cells while inadvertently activating a repair response that helps tumors rebound. Now, researchers are exploring combination strategies: using conventional chemotherapy alongside experimental MYC inhibitors or drugs that block specific DNA repair pathways, such as PARP inhibitors. Early trials in MYC-amplified small cell lung cancer and triple-negative breast cancer have shown promising results when PARP inhibitors are added to standard regimens. Moreover, diagnostic tests that measure both MYC levels and DNA repair markers could help identify patients most likely to benefit from these tailored approaches. If successful, this could transform MYC from an undruggable target into a central node in precision oncology.
\n\n
What This Means For You
\n
If you or a loved one is facing a cancer diagnosis, especially one involving aggressive or treatment-resistant disease, this research offers both insight and hope. It explains why some tumors bounce back after chemotherapy and highlights a new direction for smarter, more effective treatments. While MYC-targeting drugs are still largely in development, understanding your tumor’s molecular profile — including MYC status — may soon guide more personalized therapy choices. For the broader public, it underscores the importance of continued investment in basic cancer research, where discoveries about fundamental biology can unlock unexpected clinical advances.
\n\n
Now that we know MYC helps cancer cells repair themselves, the next critical question is: can we selectively block its repair function without disrupting its essential roles in healthy cells? Answering this will require deeper exploration of MYC’s interactions at DNA break sites and the development of highly targeted inhibitors that spare normal tissue — a challenge, but one that could redefine cancer treatment in the coming decade.
Source: ScienceDaily